MedTrace Logo

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07608718 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-05-27

No results posted yet for this study

Summary

This research study is for people with metastatic castrate-resistant prostate cancer (mCRPC). Zanzalintinib is a new drug that shows activity in mCRPC with soft tissue or visceral metastases who have progressed on prior treatment. Participants can stay in the research for up to 24 months as long as they experience clinical benefit from it. The purpose of this study is to learn if Zanzalinitib is effective in treating metastatic castrate-resistant prostate cancer.

Conditions

Interventions

DRUG

Zanzalintinib

60mg zanzalinitib will be given daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicity

Sponsors & Collaborators

  • Pedro Barata, MD, MSc

    lead OTHER

Principal Investigators

  • Pedro Barata, MD, MSc · University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2029-05-31
Completion
2030-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07608718 on ClinicalTrials.gov